IC-Vec

IC-Vec is a London-based biotechnology company specializing in the development of advanced non-viral delivery systems for gene therapy. Spun out from Imperial College London, the company focuses on a proprietary hybrid vector technology that combines the efficiency of viral vectors with the safety and scalability of synthetic systems. Their primary focus is on treating respiratory conditions, most notably cystic fibrosis, by delivering functional genetic material directly to the lungs. IC-Vec's platform aims to overcome the limitations of traditional delivery methods, such as immunogenicity and limited cargo capacity, to enable repeatable and effective genetic treatments.